Pfizer
PFE
$28.07
+1.01%
Pfizer Inc. is a global pharmaceutical giant engaged in the discovery, development, and commercialization of prescription medicines and vaccines, operating in the highly competitive drug manufacturing industry. As one of the world's largest pharma firms, it holds a leading market position with blockbuster products like Prevnar 13, Vyndaqel, and Eliquis, and generates roughly $60 billion in annual sales. The current investor narrative centers on Pfizer's strategic pivot to oncology and obesity treatments, highlighted by the promising but unproven oral GLP-1 candidate berobenatide, while the company navigates patent expirations, a recent clinical trial failure, and a historically high dividend yield that attracts income investors despite significant risks.…
PFE
Pfizer
$28.07
Related headlines
Investment Opinion: Should I buy PFE Today?
Pfizer is rated a Hold based on a balanced risk-reward profile. The analyst consensus is a Buy with an average target of $28.61, implying 6.8% upside from the current price of $26.79. The thesis is that the low forward P/E of 9.25x and high dividend yield provide downside support, but the unsustainable payout ratio and pipeline uncertainties limit upside.
Sign up to view all
PFE 12-Month Price Forecast
The AI assessment is neutral with medium confidence. The low forward P/E and high dividend yield provide a value proposition, but the unsustainable payout ratio and pipeline uncertainties cap upside. The stock is likely to trade in a range, with the base case being a gradual recovery. An upgrade to bullish would require positive pipeline news or a dividend coverage improvement, while a downgrade to bearish would occur if the dividend is cut or revenue growth turns negative.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Pfizer's 12-month outlook, with a consensus price target around $28.61 and implied upside of +1.9% versus the current price.
Average Target
$28.61
0 analysts
Implied Upside
+1.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$25 - $36
Analyst target range
The target price range spans from a low of $25.00 to a high of $35.75, with the high target implying a 33.4% upside, likely assuming successful GLP-1 development and margin expansion, while the low target suggests a 6.7% downside, pricing in patent cliff risks and pipeline failures. Recent ratings actions show a mixed trend: HSBC downgraded from Buy to Hold in July, while RBC Capital upgraded from Underperform to Sector Perform in June, reflecting shifting views on Pfizer's risk-reward. The wide spread between low and high targets indicates high uncertainty, driven by binary outcomes in the obesity drug race and the impact of patent expirations.
Bulls vs Bears: PFE Investment Factors
Pfizer presents a classic value-versus-value-trap debate. The bull case rests on a low forward P/E of 9.25x, a 6.9% dividend yield, and a return to revenue growth, while the bear case highlights a payout ratio above 100%, patent expirations, and a recent clinical failure. Currently, the bear case has slightly stronger evidence due to the unsustainable dividend and pipeline uncertainty, but the low valuation provides a cushion. The single most important tension is whether Pfizer can successfully launch new growth drivers (like berobenatide) to offset patent losses and justify the dividend. If pipeline progress is positive, the stock could re-rate higher; if not, the dividend may be cut, leading to further downside.
Bullish
- Return to Revenue Growth: Q1 2026 revenue of $14.451 billion grew 5.37% year-over-year, reversing the post-COVID slump. This marks the second consecutive quarter of growth, signaling a recovery in the core Biopharma business, which contributed $14.161 billion of total revenue.
- Attractive Forward Valuation: With a forward P/E of 9.25x versus a trailing P/E of 18.31x, the market expects a ~50% earnings increase. This low forward multiple provides a margin of safety if the company meets its EPS estimates of $2.44 for the year.
- High Dividend Yield with Coverage: Pfizer offers a 6.9% dividend yield, well above the S&P 500 average. The payout ratio of 125.75% is concerning, but positive net income of $2.688 billion in Q1 2026 and free cash flow of $9.484 billion TTM provide near-term coverage.
- Strong Gross and Operating Margins: Gross margin stands at 70.3% and operating margin at 24.7% for the trailing twelve months. These robust margins reflect Pfizer's pricing power and cost discipline, supporting profitability as revenue grows.
Bearish
- Patent Cliff Risk: Key drugs like Prevnar 13 and Eliquis face patent expirations in the coming years, which could erode revenue. The company's reliance on these blockbusters for a large portion of sales makes it vulnerable to generic competition.
- High Dividend Payout Ratio: The payout ratio of 125.75% indicates that Pfizer is paying out more in dividends than it earns, which is unsustainable long-term. This could force a dividend cut if earnings don't improve, a major risk for income investors.
- Recent Clinical Trial Failure: A significant clinical trial failure (likely in the GLP-1 space) has raised doubts about pipeline execution. This has contributed to the stock's underperformance and increased uncertainty about future growth drivers.
- Underperformance vs. Market: Pfizer's 1-year return of +6.69% lags the S&P 500's +20.37%, and its 6-month return is -2.86% versus the market's +13.87%. This relative weakness suggests persistent negative sentiment and a lack of investor confidence.
PFE Technical Analysis
Pfizer's stock has been in a broad recovery phase over the past year, with a 1-year price change of +6.69%, though this masks significant volatility. The current price of $26.79 sits at 78% of its 52-week range (low: $23.58, high: $28.75), indicating a rebound from the lows but still below the highs. This positioning suggests the stock is in a recovery mode, with room to run if momentum persists, but it has not yet reclaimed its previous highs, implying lingering bearish sentiment.
Beta
0.28
0.28x market volatility
Max Drawdown
-17.1%
Largest decline past year
52-Week Range
$24-$29
Price range past year
Annual Return
+9.1%
Cumulative gain past year
| Period | PFE Return | S&P 500 |
|---|---|---|
| 1m | +13.1% | +2.5% |
| 3m | +8.4% | +2.7% |
| 6m | +5.3% | +11.1% |
| 1y | +9.1% | +20.5% |
| ytd | +11.5% | +12.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
PFE Fundamental Analysis
Pfizer's revenue trajectory shows a return to growth, with Q1 2026 revenue of $14.451 billion, up 5.37% year-over-year, following a mixed 2025 where Q4 revenue was $17.557 billion but Q1 was $13.715 billion. The multi-quarter trend indicates a recovery from the post-COVID slump, with Q1 2026 growth accelerating from the prior year's 5.37% increase. The Biopharma segment drove nearly all revenue at $14.161 billion, while corporate nonsegment contributed $289 million, highlighting the core business's strength.
Quarterly Revenue
$14.5B
2026-03
Revenue YoY Growth
+5.4%
YoY Comparison
Gross Margin
67.3%
Latest Quarter
Free Cash Flow
$9.5B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is PFE Overvalued?
Given Pfizer's positive net income of $2.688 billion in Q1 2026, the trailing P/E ratio of 18.31x is the primary valuation metric, with a forward P/E of 9.25x, indicating the market expects significant earnings growth. The gap between trailing and forward P/E suggests an anticipated 50% earnings increase, reflecting optimism about pipeline catalysts and cost-cutting measures.
PE
18.3x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 7x~22x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks are significant. Pfizer's debt-to-equity ratio of 0.78 indicates moderate leverage, but the dividend payout ratio of 125.75% is unsustainable, as it exceeds earnings. The company's net income of $2.688 billion in Q1 2026 is positive, but the trailing twelve-month net margin of 12.4% is thin for a pharma giant. Free cash flow of $9.484 billion TTM provides some buffer, but if revenue growth stalls, the dividend could be at risk. Additionally, the company's reliance on a few blockbuster drugs for a large portion of revenue creates concentration risk, as patent expirations could significantly reduce cash flows.